|Condition:||Diabetes Mellitus Type 2|
|Brand Names:||Invokana, Vokanamet|
|Keywords:||SGLT2 inhibitors, sodium glucose co-transporter 2 inhibitors, diabetic ketoacidosis, DKA|
Please select a BNF chapter code to go to the formulary.
060102 - Antidiabetic Drugs
|Date||Committee Name||Narrative||Traffic Light Status Traffic Light Status|
|07 February 2018||Prescribing Clinical Network||
Not a preferred treatment option.
See guidelines below and associated documentation for further information
PCN noted that Canagliflozin is a treatment option in NICE TA 315 & TA390
|Type:||Document (click to view)||Review Date|
|Guidelines (Local)||Diabetes Type 2 -Treatment Guidelines - February 2018||February 2021|
|NICE TA||NICE TA315 - Canagliflozin in combination therapy for treating Type 2 Diabetes - June 2014|
|NICE TA||NICE TA390 - SGLT-2s for treating Type 2 diabetes - May 2016|
|Miscellaneous||SGLT2 inhibitors - Prescribing Initiation checklist - Aug 2015||August 2017|
|Miscellaneous||SGLT2 inhibitors - Prescribing Safety advice - Aug 2015||August 2017|
|Information||Hypoglycaemic agents -Preferred choices - February 2018||February 2021|
|Information||Blood glucose control - Treatment algorithm - February 2018||February 2021|
|Information||Antidiabetic treatments comparison- PrescQIPP resource - February 2018||February 2021|
No Supplementary Documents returned.